Med Tech Gurus

What if the future of interventional cardiology isn't just better devices—but robotic precision? In this episode of Med Tech Gurus, we sit down with Dr. Philippe Bencteux, founder and president of RoboCath, a pioneering company developing robotic platforms designed to transform cardiovascular and neurovascular interventions. A neuroradiologist turned entrepreneur, Dr. Bencteux launched RoboCath after witnessing how access to specialized vascular expertise can determine whether patients live or die—particularly in hospitals lacking advanced interventional capabilities. His vision: bring robotic precision and eventually remote care to life-saving endovascular procedures. We explore the evolution of RoboCath's robotic systems, including the R1 platform, which demonstrated more than 98% technical success in multicenter studies, and the company's next-generation system now entering first-in-human trials for coronary artery disease. Dr. Bencteux shares how robotics can dramatically improve physician safety by reducing radiation exposure and physical strain in the cath lab, while also increasing procedural precision and enabling more complex interventions. If you're interested in robotic surgery, interventional cardiology innovation, digital health, AI-driven medical devices, or the future of remote healthcare, this episode offers a fascinating look at how robotics could reshape the next era of cardiovascular treatment.

What if getting breakthrough devices to the right patients wasn't a guessing game — but a data-driven science? In this episode of Med Tech Gurus, we sit down with Mike Monovoukas, CEO and Co-Founder of AcuityMD, one of the fastest-growing platforms in MedTech. Mike shares how his team is turning mountains of messy healthcare data into clear, actionable insights — helping innovators pinpoint the right physicians, facilities, and patient populations, and transforming how devices reach the people who need them most. We explore how AcuityMD is powering precision targeting through AI, why democratizing market intelligence helps level the playing field for new entrants, and how smarter commercialization can unlock access for underserved communities — including their work helping EPI bring the Alpha-Stim device to veterans struggling with pain, insomnia, and anxiety. From designing platforms built specifically for MedTech, to making complex data simple for frontline sales teams, to reshaping how companies scale, Mike delivers a masterclass in building for the future of commercialization — where evidence, empathy, and AI come together.

In this episode of Med Tech Gurus, we sit down with Dr. Adam S. Arthur, Chief Medical Officer for Medtronic's Neurovascular business — and one of the most influential voices in modern stroke care. With more than 20 years as a practicing neurosurgeon, clinical researcher, and academic leader, Dr. Arthur has helped redefine standards of care for ischemic stroke, hemorrhagic stroke, carotid disease, and neurovascular innovation worldwide. Now at Medtronic, he's leading the charge to translate real-world clinical insight into breakthrough devices that scale — from next-generation thrombectomy tools to new applications for established technologies like Onyx, and a pipeline of neurostimulation, robotics, and endovascular therapies that promise to change what's possible for brain health. Dr. Arthur shares powerful lessons from decades of clinical trials, including why "the devil is in the details," how honest collaboration between physicians and industry accelerates innovation, and why failing fast is often the quickest path to breakthroughs. He also offers an exciting look at the future: remote robotics, closed-loop vagus nerve stimulation, and new ways to reach stroke patients with life-saving precision. If you care about the future of stroke care, neurovascular devices, or scaling innovation responsibly, this episode delivers a masterclass from one of the field's true thought leaders.

In this episode of Med Tech Gurus, we welcome Neil Klompas, Chief Executive Officer of Augurex Life Sciences. With more than two decades of experience leading companies at the intersection of diagnostics, rheumatology, and translational medicine, Neil is pioneering a new era of autoimmune biomarker discovery. Under his leadership, Augurex developed SpineStat, the world's first blood test designed to identify axial spondyloarthritis (AxSpA)—a chronic inflammatory spinal disease that affects millions yet often goes undiagnosed for nearly a decade. By leveraging the anti-14-3-3η autoantibody in combination with CRP, SpineStat is helping clinicians detect disease earlier, prevent irreversible spinal damage, and even reduce opioid dependence through faster, targeted treatment. Neil shares how engaging early with regulators helped Augurex earn FDA Breakthrough Device Designation, why he believes rheumatology is poised for its "oncology moment," and how keeping his team centered on the patient journey drives innovation every day. If you're passionate about precision diagnostics, regulatory navigation, and building mission-driven teams, this episode is a masterclass in turning unmet medical need into measurable clinical impact.

What if artificial intelligence could spot hospital-acquired infections days before symptoms appear? In this episode of Med Tech Gurus, we sit down with Benedikt von Thüngen, CEO and Co-Founder of Sanome, a company redefining hospital care through AI-powered clinical decision support. After enduring profound personal and professional loss, including the collapse of his seed round and the death of loved ones, Benedikt rebuilt his company around one mission—helping clinicians understand patients earlier and intervene faster Under his leadership, Sanome became the first UK-based AI company to earn Class IIb certification for HAI prediciton. Its Memory Platform predicting infections up to 72 hours sooner than conventional methods with the potential to save each NHS Trust over £1.1 million per year. Benedikt shares a powerful story of resilience, transparency, and innovation—proving that when data, determination, and purpose align, technology can truly save lives.

What if we could take the guesswork out of cancer treatment—and move from try and hope to test and know? In this episode of Med Tech Gurus, we sit down with Jim Foote, CEO and Founder of First Ascent Biomedical, whose mission began after losing his son to cancer. That experience became the driving force behind Functional Precision Medicine (FPM)—a groundbreaking approach that combines tumor testing, genomics, and AI to rank the most effective drugs for each patient in just ten days Backed by a Nature Medicine study showing an 83% patient benefit rate, First Ascent is proving that personalization saves lives. With automation reducing lab times from hours to minutes and new CLIA-certified labs accelerating access, Jim and his team are reshaping how cancer care is delivered. From building trust with clinicians to leading through loss, Jim shares a powerful story of innovation, resilience, and purpose that every medtech leader can learn from.

What if the missing link in treating autoimmune disease wasn't a new drug—but a better way to measure stress? In this episode of Med Tech Gurus, we sit down with Dr. Andrew Holman, CEO of Inmedix and the innovator behind CloudHRV, the first FDA-cleared platform to measure stress biology with medical-grade precision .At a time when 75% of autoimmune treatments fail—costing billions and leaving patients without answers—CloudHRV delivers actionable insights in just five minutes reframing how clinicians think about chronic disease. Dr. Holman takes us inside his two-decade journey building Inmedix, from early IP strategy to securing partnerships with global pharma. Along the way, he shares lessons on leveraging licensing as a growth strategy, building a culture of innovation, and aligning science, business, and patient care in the pursuit of transformative healthcare solutions. Whether you're a founder, investor, or clinician, this conversation will reshape how you think about precision medicine and the future of patient-centered innovation.

What if solving a widespread medical condition didn't require surgery, expensive implants, or harsh medications—but could be done by simply putting on a sock? In this episode of Med Tech Gurus, we sit down with Isaac Oppenheim, CEO and Founder of Zida, a company pioneering wearable neuromodulation at the intersection of aging, textiles, and healthcare. Inspired by his grandfather's struggle with overactive bladder (OAB), Isaac developed the Zida Control Sock—the first FDA-cleared, Medicare-covered, home-use neuromodulation device for OAB. From his early career in textiles and wearable tech with brands like Nike and Lululemon, to navigating FDA clearance and CMS reimbursement without institutional capital, Isaac's journey shows what happens when design thinking, perseverance, and patient-centered innovation come together. Clinical trials show nearly 80% success rates, giving millions of patients renewed confidence, independence, and quality of life Whether you're an entrepreneur building medtech from scratch, a clinician seeking better therapies for aging populations, or an innovator curious about the future of neuromodulation, this episode is packed with lessons on resilience, creativity, and making healthcare more human.